Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures - Homepage
Triathlon Medical Ventures - Team
Triathlon Medical Ventures - Investment Focus
Triathlon Medical Ventures - Investment Strategy
Triathlon Medical Ventures - Investment Criteria
Contact Triathlon Medical Ventures - Evaluation Process
Triathlon Medical Ventures - Portfolio
Triathlon Medical Ventures - Links
Contact Contact Triathlon Medical Ventures

Triathlon Medical Ventures

 

 

 

 


Biopharmaceutical
AERPIO THERAPEUTICS, INC.
AKEBIA THERAPEUTICS, INC.
BIOVEX, INC.
CoLUCID PHARMACEUTICALS, INC.
ENDOCYTE
JUVENTAS THERAPEUTICS
Medical Device
CELLERATION, INC.
EXPANDING ORTHOPEDICS, INC.
MITRALIGN, INC.
REMON MEDICAL TECHNOLOGIES, INC.
RENAL SOLUTIONS, INC.


Biopharmaceutical Portfolio


PORTFOLIO



AERPIO THERAPEUTICS, INC.
www.aerpio.com

Publicly traded August 2017

Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpio's lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. Aerpio was created in in 2011 as a spin-out transaction from Akebia Therapeutics.

back to top
 


PORTFOLIO



AKEBIA THERAPEUTICS, INC.
www.akebia.com

Publicly traded March 2014

Akebia Therapeutics is a biopharmaceutical company Triathlon formed by in-licensing two drug development programs that had been maturing within P&G Pharmaceuticals for many years with significant investment and internal support from P&G scientists. These programs are focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. The lead compound, vadadustat, is an investigational product being studied in patients with anemia due to chronic kidney disease (CKD).

back to top
 


PORTFOLIO



BIOVEX, INC.

Acquired by Amgen March 2011

BioVex is a biotechnology company focused on the development of novel biologics for the treatment of cancer using genetically modified Herpes virus to replicate within tumors and produce an immunostimulatory anti-tumor immune response.

Biovex' lead product, T-Vec, is marketed by Amgen as IMLYGIC™ (Talimogene Laherparepvec) approved in 2015 for treatment of Stage III and IV melanoma and is the first oncolytic viral therapy in the US.

back to top
 


PORTFOLIO



CoLUCID PHARMACEUTICALS, INC.

Publicly traded May 2015 then Acquired by Eli Lilly March 2017

CoLucid Pharmaceuticals, Inc. is a CNS-focused company based on the in-licensing and development of a potent and selective small molecule that has the potential to be useful in the acute treatment and/or prevention of migraine headaches.

back to top


PORTFOLIO



ENDOCYTE
www.endocyte.com

Publicly traded February 2011

Endocyte is developing receptor-targeted imaging and therapeutic agents for the diagnosis and treatment of cancer and autoimmune diseases. The technology is based upon work performed by Dr. Philip S. Low at Purdue University.

back to top


PORTFOLIO



JUVENTAS THERAPEUTICS
www.juventasinc.com

Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. This therapeutic approach is based on research originating at the Cleveland Clinic. Lead product JVS-100 is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that is produced too briefly to have a long-term beneficial impact, but has been shown to recruit the body's own stem cells and promote tissue repair. By manufacturing SDF-1 and injecting it at the site of damage, the protein stays there longer and attracts the stem cells needed for tissue repair and is being evaluated in a broad range of disease states.

back to top
 


Medical Device Portfolio


PORTFOLIO



CELLERATION, INC.

Acquired by Alliqua BioMedical May 2015

Celleration®, Inc. was founded to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology™ utilizes ultrasonic sound waves to produce an energized mist of sterile saline in a non-contact fashion for treatment of chronic wounds such as a diabetic foot ulcers.

back to top


PORTFOLIO



EXPANDING ORTHOPEDICS, INC.

Acquired by CoreLink June 2018

Expanding Orthopedics is a medical device company developing orthopedic implants that use expandable metal and polymer components in bone to add greater strength with reduced surgical intrusion.

back to top
 


PORTFOLIO



MITRALIGN, INC.
www.mitralign.com

Combining surgical precision with interventional therapy, Mitralign is developing an innovative, catheter-based method to treat triscuspid valve and mitral valve regurgitation that not only provides an alternative to open heart surgery but simulates the surgical repair technique.

back to top
 


PORTFOLIO



REMON MEDICAL TECHNOLOGIES, INC.

Acquired by Boston Scientific August 2007

Remon Medical Technologies, Inc. develops and commercializes smart, miniature implants which enable physicians to assess and treat a variety of medical conditions in a non-invasive manner. Remon's unique platform has broad applications for patient management, post-operative monitoring, nerve and tissue stimulation, and local drug delivery/release, with the focus on Congestive Heart Failure.

back to top


PORTFOLIO



RENAL SOLUTIONS, INC.

Acquired by Fresenius November 2007

Renal Solutions, Inc., is a medical device company developing a solution for the home dialysis market utilizing sorbent-based toxin removal technology. Using sorbent dialysate regeneration and a unique pressure controlled blood movement system, hemodialysis can be delivered safely and cost effectively in the home or clinical environment. The Allient® Sorbent Hemodialysis System requires only 6 liters of tap water. This capability eliminates the need for complex technology to create a purified water source as with conventional dialysis technology. The Allient System is transportable and can be used anywhere 110V power and tap water can be accessed.

back to top


 
Copyright © 2004 - Triathlon Medical Ventures - All Rights Reserved Web Site Credits Legal Notices & Privacy Policy